Nasdaq
$1.06▼ 2.30%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $168.2MShares out 1.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
21- 3d agoPre-market26.10.22 20:018-KKey event#●●●#●●●#●●●
FRACTYL HEALTH, INC.
Fractyl Health is reducing its workforce by approximately 45% and discontinuing its Rejuva gene therapy program to sharpen its strategic focus on the Revita program. These measures are expected to reduce quarterly cash burn by approximately 50%, extending the company's cash runway into Q2 2027, while President and Chief Product Officer Jay Caplan will retire effective October 30, 2026.…more
$1.06-2.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.16Pre-market26.10.16 20:018-KKey event
FRACTYL HEALTH, INC.
Fractyl Health announced positive topline six-month results from its REMAIN-1 pivotal study, which evaluates the Revita DMR System for weight maintenance after GLP-1 therapy discontinuation. The Revita group demonstrated a statistically significant reduction in weight regain compared to sham (p=0.0023), and the company plans to submit a De Novo marketing application to the FDA in late Q4 2026.…more
$1.06-2.30%vs prev closeView filingShare - 10.13Regular26.10.14 02:48SCHEDULE 13GOwnership
FRACTYL HEALTH, INC.
Catalio Capital Management, LP has filed a Schedule 13G, reporting a beneficial ownership of more than 5% in Fractyl Health, Inc. This filing officially discloses the firm's significant stake in the company.…more
$1.06-2.30%vs prev closeView filingShare
20 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.22 20:07#●●●#●●●#●●●
Fractyl Health Shifts Focus to Revita Development and Announces Workforce Reduction…more
Fractyl Health is prioritizing the development of its Revita weight maintenance therapy and reducing its workforce to align with clinical goals. The company is also discontinuing its Rejuva gene therapy program to extend its cash runway into the second quarter of 2027.…more
$1.06-2.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.16Regular26.10.16 23:01
●●●●●●●● ●●●●● ●●●●●●
Fractyl Health shares plummeted as investors reacted to a class action lawsuit and concerns over the effectiveness of its weight-loss treatment, despite positive six-month clinical trial results. The stock hit a new 52-week low following analyst downgrades and allegations regarding previous trial disclosures.…more
$1.06-2.30%vs prev closeShareBenzinga - 10.16Pre-market26.10.16 20:00
●●●●●●●● ●●●●● ●●●●●●
Fractyl Health announced that its Revita device met the six-month co-primary endpoint in the REMAIN-1 study, demonstrating a statistically significant reduction in weight regain. While the company plans to submit a De Novo marketing application to the FDA in late 2026, the path to commercialization remains subject to further regulatory review.…more
$1.06-2.30%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report